What is HC Wainwright's Forecast for Kamada FY2025 Earnings?

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Analysts at HC Wainwright lowered their FY2025 earnings estimates for shares of Kamada in a report released on Thursday, March 6th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.28 for the year, down from their prior forecast of $0.31. HC Wainwright currently has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada's FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.54 EPS.

Kamada Stock Performance

Shares of NASDAQ:KMDA traded down $0.13 during trading on Monday, reaching $7.21. 48,800 shares of the stock were exchanged, compared to its average volume of 254,832. The firm's 50-day moving average price is $7.20 and its 200 day moving average price is $6.20. The firm has a market cap of $414.60 million, a price-to-earnings ratio of 25.77, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97. Kamada has a 12-month low of $4.74 and a 12-month high of $9.15.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC lifted its position in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after acquiring an additional 8,260 shares in the last quarter. Aristides Capital LLC lifted its position in shares of Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after purchasing an additional 6,850 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 1,549 shares during the period. JPMorgan Chase & Co. acquired a new stake in Kamada during the 4th quarter valued at $67,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Kamada during the 3rd quarter valued at $77,000. Institutional investors and hedge funds own 20.38% of the company's stock.

Remove Ads

Kamada Dividend Announcement

The firm also recently announced a -- dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be paid a $0.20 dividend. The ex-dividend date is Monday, March 17th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.